Lytus Telemedicine is a one-of-a-kind patient-centric product in the industry that allows health care practitioners to deliver and patients to receive unrivaled health care services while remaining fully compliant with all current regulatory requirements.
FREMONT, CA: Lytus Technologies Holdings, a technology platform services company with active users and business operations in the United States and India, announced the launch of Lytus Telemedicine, a robust platform of telemedicine/telehealth services that is one of the premier platforms to serve the United States and India markets actively.
Mr. Dharmesh Pandya, Lytus founder, and CEO commented: “Amid the current global pandemic, Lytus has worked diligently in both the U.S. and India to help meet the needs of patients by bringing them closer to their physicians to receive the care they need in the safest and most efficient manner possible. The current and dire COVID-19 situation in India has highlighted the importance and need for telemedicine services for patients. The demand for this type of virtual medical diagnosis and treatment is growing rapidly in India. Clearly, we do not believe this is a fad telemedicine and telehealth bring an abundance of efficiencies to clinical care, and is here to stay. In fact, India’s Prime Minister stated recently that telemedicine service needs be expanded in the country’s rural areas because it has played such an important and beneficial role for patients in home isolation. Virtually all the restrictions that have heretofore impeded the growth of the telemedicine industry in delivering healthcare have been removed by almost all governmental regulatory bodies around the world.”
“We also believe that it is very clear there will be substantial changes in the provisioning and delivery of health care in our target markets for telemedicine services. This has led to a more favorable environment for Lytus to leverage the breakthrough technological applications available to us. We intend to be well positioned to take advantage of these opportunities quickly, through the assistance of our business partners and our network of technology vendors with whom we have built long-term working relationships,” added Pandya.
Lytus Telemedicine is a one-of-a-kind patient-centric product in the industry that allows health care practitioners to deliver and patients to receive unrivaled health care services while remaining fully compliant with all current regulatory requirements. Within the Lytus Telemedicine platform, Lytus will employ digital communication technologies such as medical devices, video capabilities, and data gathering approaches. In addition, Lytus has established into long-term privileged supply agreements with prominent worldwide suppliers of telemedicine technology and remote patient management devices to support both the U.S. and India markets.
Lytus acquired a majority stake in Global Health Sciences (GHSI), a telemedicine developer who aspires to deliver management and technology solutions to hospital networks, university medical schools, physician networks, and individual practices in the United States 2020. James Tuchi, GHSI’s CEO and founder, is an industry veteran with experience launching telemedicine services in the United States and worldwide. GHSI’s proprietary delivery platform combines medical monitoring devices, video capabilities, and data collecting procedures with digital communication tools. Conversational computing, Intelligent Robotic Process Automation (iRPA), and Machine Learning are among the A.I. ecosystem elements used by the GHSI platform (ML). This technology is presently being pushed out in New Jersey, Illinois, Florida, and Texas, with about 125 medical practitioner practices using it to serve about 3,000 eligible patients through hospital and clinic networks.
Dr. Sanjeiiv Geeta Chaudhry, a health sector veteran with extensive experience running major enterprises and driving innovation and growth, leads the Lytus telemedicine business in India. Lytus’ telemedicine business in India has begun repurposing its existing local cable operator network infrastructure to establish Local Health Clinics/diagnostic centers (LHC). For every 5,000 consumers, there will be one dedicated LHC, which experienced healthcare professionals will staff. We anticipate that LHCs will provide clients with extra patient services that cannot be given remotely via gadget telemedicine.
ECGs, EKGs, ultrasound scans, blood and urine testing, and other health vitals will all be available at the LHCs. The LHC network will serve as a vital link between patients, clinicians, and supportive hospital partners for improved integration. The company also plans to use the LHC network to supply pharmaceuticals. The beta testing of services in India has revealed the unique benefit of 24/7 company-employed physicians handling inbound health calls to provide prompt resolution of callers’ health needs. In contrast, the national call center has access to specialist services for diagnosis and prescription fulfillment on the back end.